These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 3707669)

  • 41. Is canrenone the major metabolite of spironolactone?
    Merkus FW
    Clin Pharm; 1983; 2(3):209-10. PubMed ID: 6883952
    [No Abstract]   [Full Text] [Related]  

  • 42. Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.
    Karim A; Zagarella J; Hutsell TC; Dooley M
    Clin Pharmacol Ther; 1976 Feb; 19(2):177-82. PubMed ID: 1261155
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro and in vivo availability of spironolactone from oral dosage forms.
    Chao AY; Sanvordeker DR; Zagarella J; Mattes K; Nicholova B; Karim A
    J Pharm Sci; 1976 Nov; 65(11):1630-4. PubMed ID: 993995
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations, including preliminary data on two spironolactone metabolites.
    Tidd MJ; Collins WT; Chamberlain J
    J Int Med Res; 1976; 4(2):86-95. PubMed ID: 1037443
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
    Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of spironolactone in man.
    Abshagen U; Rennekamp H; Luszpinski G
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Dec; 296(1):37-45. PubMed ID: 1012347
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Drug treatment in the elderly: special aspects of diuretics (author's transl)].
    Mühlberg W; Platt D
    Aktuelle Gerontol; 1982 Jul; 12(4):134-8. PubMed ID: 6126136
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quantitation of spironolactone and its metabolite, canrenone, in human serum by thin-layer spectrofluorimetry.
    van der Merwe PJ; Müller DG; Clark EC
    J Chromatogr; 1979 Apr; 171():519-21. PubMed ID: 546864
    [No Abstract]   [Full Text] [Related]  

  • 49. Influence of food on the bioavailability of spironolactone.
    Overdiek HW; Merkus FW
    Clin Pharmacol Ther; 1986 Nov; 40(5):531-6. PubMed ID: 3769384
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone.
    Ho PC; Bourne DW; Triggs EJ; Smithurst BA
    Eur J Clin Pharmacol; 1984; 27(4):435-9. PubMed ID: 6519150
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediate-and extended-release formulations in healthy subjects.
    Marier JF; Ducharme MP; DiMarco M; Di Spirito M; Morelli G; Tippabhotla SK; Badri N; Rampal A; Monif T
    Clin Ther; 2006 Dec; 28(12):2070-80. PubMed ID: 17296463
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aspects on pharmacokinetics of some diuretics.
    Beermann B
    Acta Pharmacol Toxicol (Copenh); 1984; 54 Suppl 1():17-29. PubMed ID: 6369882
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Determination of the serum concentration of spironolactone and its metabolites by high-performance liquid chromatography.
    Overdiek JW; Hermens WA; Merkus FW
    J Chromatogr; 1985 Jun; 341(2):279-85. PubMed ID: 4030980
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Spironolactone and canrenoate-K: relative potency at steady state.
    Ramsay L; Asbury M; Shelton J; Harrison I
    Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Spironolactone metabolism in normal subjects and in patients with liver cirrhosis.
    Váradi A; Fehér T; Bodrogi L; Koref O
    Arzneimittelforschung; 1977; 27(8):1618-20. PubMed ID: 578759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats.
    Sadée W; Abshagen U; Finn C; Rietbrock N
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 283(3):303-18. PubMed ID: 4276758
    [No Abstract]   [Full Text] [Related]  

  • 57. High-performance liquid chromatographic determination of canrenone, a major metabolite of spironolactone, in body fluids.
    Neurath GB; Ambrosius D
    J Chromatogr; 1979 Jun; 163(2):230-5. PubMed ID: 541378
    [No Abstract]   [Full Text] [Related]  

  • 58. Spironolactone and potassium canrenoate in normal man.
    Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
    Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of bendroflumethiazide.
    Beermann B; Groschinsky-Grind M; Lindström B
    Clin Pharmacol Ther; 1977 Oct; 22(4):385-8. PubMed ID: 902450
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Simultaneous determination of spironolactone and its metabolites in human plasma.
    Jankowski A; Skorek-Jankowska A; Lamparczyk H
    J Pharm Biomed Anal; 1996 Jun; 14(8-10):1359-65. PubMed ID: 8818057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.